论文部分内容阅读
Objective: The aim of our study was to evaluate the serum levels of CA19-9 in patients with non-small cell lung cancer (NSCLC) and to analyze the relationship between serum levels of CA19-9 and metastasis. Methods: Serum levels of CA19-9 in 1200 NSCLC patients from February 2006 to August 2011 were evaluated retrospectively. The relationship between serum levels of CA19-9 and sites of metastasis were analyzed. Results: Of the 1200 patients, 528 were stage IV and the positive rate of CA19-9 was 32% (169 cases) and 288 stage III, positive rate 20% (58 cases); 144 stage II, positive rate 12% (17cases); 240 stage I, positive rate 3% (7 cases). There were statistical differences from stage I to stage IV (P 0.05). Conclusion: Positive rate of CA19-9 increases accordingly from stage I to stage IV. The serum levels of CA19-9 may be as an indicator for metastases in patients with NSCLC, especially for bone metastasis in stage IV diseases.